Bank of New York Mellon
RXRX icon

Bank of New York Mellon’s Recursion Pharmaceuticals RXRX Stock Holding History

Bank of New York Mellon’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.02M Buy
1,639,167
+176,536
+12% +$588K ﹤0.01% 2330
2026
Q1 		$4.49M Buy
1,462,631
+331,048
+29% +$1.28M ﹤0.01% 2375
2025
Q4 		$4.63M Sell
1,131,583
-238,074
-17% -$1.18M ﹤0.01% 2368
2025
Q3 		$6.68M Buy
1,369,657
+288,454
+27% +$1.51M ﹤0.01% 2159
2025
Q2 		$5.47M Buy
1,081,203
+217,979
+25% +$1.07M ﹤0.01% 2220
2025
Q1 		$4.57M Buy
863,224
+12,588
+1% +$91.8K ﹤0.01% 2268
2024
Q4 		$5.75M Sell
850,636
-75,482
-8% -$507K ﹤0.01% 2215
2024
Q3 		$6.1M Sell
926,118
-134,686
-13% -$966K ﹤0.01% 2197
2024
Q2 		$7.96M Buy
1,060,804
+178,994
+20% +$1.56M ﹤0.01% 2085
2024
Q1 		$8.79M Buy
881,810
+48,535
+6% +$540K ﹤0.01% 2026
2023
Q4 		$8.22M Buy
833,275
+199,265
+31% +$1.42M ﹤0.01% 2087
2023
Q3 		$4.85M Buy
634,010
+37,317
+6% +$372K ﹤0.01% 2332
2023
Q2 		$4.46M Buy
596,693
+67,536
+13% +$473K ﹤0.01% 2385
2023
Q1 		$3.53M Buy
529,157
+23,710
+5% +$188K ﹤0.01% 2491
2022
Q4 		$3.9M Buy
505,447
+1,506
+0.3% +$14.8K ﹤0.01% 2478
2022
Q3 		$5.36M Buy
503,941
+104,588
+26% +$1.06M ﹤0.01% 2258
2022
Q2 		$3.25M Buy
399,353
+25,653
+7% +$172K ﹤0.01% 2551
2022
Q1 		$2.68M Buy
373,700
+6,294
+2% +$66.9K ﹤0.01% 2781
2021
Q4 		$6.29M Buy
367,406
+263,379
+253% +$4.96M ﹤0.01% 2344
2021
Q3 		$2.39M Buy
104,027
+30,633
+42% +$868K ﹤0.01% 2877
2021
Q2 		$2.68M Buy
+73,394
New +$2.17M ﹤0.01% 2817

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Bank of New York Mellon's RXRX Position: Q2 2026 in Review

Bank of New York Mellon increased its Recursion Pharmaceuticals (RXRX) stake by 12% in Q2 2026, buying an estimated $588K and bringing the position to 1,639,167 shares worth $6.02M. The position accounts for ﹤0.01% of the portfolio, ranked #2330.

Bank of New York Mellon first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $8.79M in Q1 2024. 218 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Bank of New York Mellon held 1,639,167 shares of Recursion Pharmaceuticals worth $6.02M as of Q2 2026.
  • Bank of New York Mellon bought 176,536 Recursion Pharmaceuticals shares in Q2 2026, an estimated $588K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2330 holding.
  • Bank of New York Mellon first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Bank of New York Mellon's Recursion Pharmaceuticals position peaked at $8.79M in Q1 2024.
  • 218 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.